WEKO3
アイテム
Current status of hepatocellular carcinoma treatment in Japan: Hepatic arterial infusion chemotherapy
https://doi.org/10.24517/00026809
https://doi.org/10.24517/00026809a4aa2e58-d6fb-47c8-aa7d-091949a595b5
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
HO-PR-YAMASHITA-T-15.pdf (381.9 kB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2017-10-05 | |||||||
| タイトル | ||||||||
| タイトル | Current status of hepatocellular carcinoma treatment in Japan: Hepatic arterial infusion chemotherapy | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | journal article | |||||||
| ID登録 | ||||||||
| ID登録 | 10.24517/00026809 | |||||||
| ID登録タイプ | JaLC | |||||||
| 著者 |
Yamashita, Tatsuya
× Yamashita, Tatsuya |
|||||||
| 著者別表示 |
山下, 竜也
× 山下, 竜也
|
|||||||
| 提供者所属 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | 金沢大学先進予防医学研究センター / 金沢大学医薬保健研究域医学系 | |||||||
| 書誌情報 |
Clinical Drug Investigation 巻 32, 号 SUPPL. 2, p. 15-23, 発行日 2012-08-08 |
|||||||
| ISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 1173-2563 | |||||||
| NCID | ||||||||
| 収録物識別子タイプ | NCID | |||||||
| 収録物識別子 | AA11030166 | |||||||
| DOI | ||||||||
| 関連タイプ | isVersionOf | |||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | 10.2165/1163022-S0-000000000-00000 | |||||||
| 出版者 | ||||||||
| 出版者 | Adis (Adis Data Information BV.) | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Hepatic arterial infusion chemotherapy (HAIC) allows the long-term administration of cytotoxic drugs to the liver. In Japan, HAIC has traditionally been used to treat patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or multiple intrahepatic lesions, or both. The most common chemotherapy drugs used for HAIC in Japan are 5-fluorouracil and cisplatin. Although HAIC is associated with a high rate of response in some studies, it is not associated with a survival benefit. Furthermore, HAIC is associated with complications that are not observed with systemic chemotherapy, including peptic ulcer, arterial occlusion and port infection. A molecular targeted agent, sorafenib, recently became the standard therapy for advanced HCC on the basis of data from two randomized controlled trials. For this reason, the position of HAIC in the treatment of advanced HCC in Japan is under discussion. Clinical trials must be undertaken to establish standardized protocols and regimens for HAIC, and to determine the efficacy of HAIC in comparison with other therapies for HCC. Without evidence from such trials, HAIC may not find an established role in the treatment of HCC, and may even fall out of use. Recent evidence suggests that HAIC may be useful in combination with molecular targeted therapy; this is currently being investigated in a number of clinical trials. © 2012 Adis Data Information BV. All rights reserved. | |||||||
| 著者版フラグ | ||||||||
| 出版タイプ | AM | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||
